Clinical Trial Update: Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor [Phase 1]

View source ↗

Summary

Phase I study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of HLX97, a KAT6A/B inhibitor, in patients with advanced or metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• HLX97

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Advanced/Metastatic Solid Tumors | Phase 1 | Status: NOT_YET_RECRUITING